Categories Analysis, Health Care, U.S. Markets News

European competition threatens AbbVie’s run of top-selling Humira

US pharma giant AbbVie Inc (ABBV) cut its overseas sales forecast on Friday for its offering Humira, on expected pricing cuts to compete in Europe.

Chief Executive Officer Richard Gonzalez, in a conference call, said, “we’ve seen discounting at ranges from as low as 10 percent to as high as around 80 percent.”

European competition threatens AbbVie's run of top-selling Humira
AbbVie scientist looks at experimental results through a microscope. (Courtesy: AbbVie)

According to AbbVie chief, Nordic countries saw the highest cut, especially in a time when the market thinks cheaper biosimilar competition will continue to be strong in the coming year in the continent as well.

Analysts expect the competition to adversely affect, and gain more momentum in 2020, with Mylan NV (MYL), Biogen Inc (BIIB) Amgen Inc (AMGN) and Novartis AG (NOVN) all starting the sales of biosimilar versions of Humira in Europe. this has caused quite a bit of unrest amongst investors, especially when the blockbuster prescription medicine brings in about two-thirds of AbbVie’s top line.

AbbVie third quarter 2018 Earnings Infographic

In the US, however, AbbVie is safe, since biosimilar competition is not expected until 2023. Outside the US, the medical giant sees a 26-27% drop in Humira sales next year, more than the earlier expected 18-20% slip.

In the last reported quarter, total Humira sales were 9% higher at $5.12 billion. Apart from it, leukemia drug Imbruvica also exhibited higher-than-expected sales in the period, hitting $972 million — much higher than the analyst consensus of $885.6 million. Maybe, these strong fundamentals could be the reason for the stock not reacting much to the CEO comments, as it remained flat at $79.77 following the outlook.

 

Get access to timely and accurate verbatim transcripts that are published within hours of the event

Most Popular

Infographic: Key highlights from Constellation Brands (STZ) Q1 2023 earnings results

Constellation Brands, Inc. (NYSE: STZ) reported first quarter 2023 earnings results today. Net sales increased 17% year-over-year to $2.3 billion. Net income attributable to CBI was $390 million, or $2.06

Walgreens Boots Alliance (WBA) Q3 profit drops on lower revenues; results beat

Walgreens Boots Alliance, Inc. (NASDAQ: WBA) on Thursday said its third-quarter revenues decreased. As a result, the healthcare service company's adjusted profit declined but exceeded consensus estimates. Net profit, on

ANGO Stock: Is it the right time to invest in AngioDynamics now?

The performance of AngioDynamics, Inc. (NASDAQ: ANGO) has not been very impressive lately, despite being part of a rapidly growing industry. But the company's efforts to bring innovation to the

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top